Interview, Fireside Chat, Other
Samarth Kulkarni, CEO, CRISPR Therapeutics
- In approximately 50 years, medicine is expected to shift away from oral pills toward one-time genomic procedures that prevent or cure diseases, with CRISPR technology potentially delivering lifetime cures for common conditions including heart disease, diabetes, cancer, and almost all known diseases.
- The biotech sector is projected to transition from risk-focused intellectual property debates to a commercial dialogue regarding the volume of medicines available within the next five years, characterized by a "roaring 20s" driven by converging technologies and improved underwriting feasibility.
- Industry practices are anticipated to evolve toward an industrialized analysis of thousands of guides to ensure reliability, with companies expected to complete safety risk mitigation and the FDA becoming increasingly comfortable with the safety and risk-benefit profiles of CRISPR therapies.
- Specific technical expectations include in vivo gene editing via a single injection achieving 80% to 90% liver editing efficiency, a future shift from ex vivo to more efficient in vivo editing methods, and non-medical applications such as non-browning produce affecting daily life.
- Investment strategies anticipate a period of aggressive capital allocation supported by strong balance sheets, while inefficient funding of subscale companies is expected to disappear as the industry matures.
- Operational plans involve recapitulating natural mutations to reactivate fetal hemoglobin for treating sickle cell and thalassemia, with long-term patient monitoring scheduled for 15 years to assess safety.
- Clinical trial methodologies may shift to reduce the necessity for large randomized control trials for gene therapies, citing a distinct "black and white" effect observed in patients, while multiple myeloma drug programs aim to develop a "best in class" iteration if the current version fails.
- Given an expected 80% failure rate for industry efforts, strategies will focus on celebrating failure and maintaining team morale as a necessary component of the development cycle.